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Background: Recent evidence has demonstrated the role of angiogenesis in the pathogenesis of pulmonary
fibrosis. Endostatin, a proteolytic fragment of collagen XVIII, is a potent inhibitor of angiogenesis. The aim of our
study was to assess whether endostatin has beneficial effects on bleomycin (BLM)-induced pulmonary fibrosis in
rats.
Methods: The rats were randomly divided into five experimental groups: (A) saline only, (B) BLM only, (C) BLM plus
early endostatin treatment, (D) BLM plus late endostatin treatment, and (F) BLM plus whole-course endostatin
treatment. We investigated the microvascular density (MVD), inflammatory response and alveolar epithelial cell
apoptosis in rat lungs in each group at different phases of disease development.
Results: Early endostatin administration attenuated fibrotic changes in BLM-induced pulmonary fibrosis in rats.
Endostatin treatment decreased MVD by inhibiting the expression of VEGF/VEGFR-2 (Flk-1) and the activation of
extracellular signal-regulated protein kinase 1/2 (ERK1/2). Endostatin treatment also decreased the number of
inflammatory cells infiltrating the bronchoalveolar lavage fluid during the early inflammatory phase of BLM-induced
pulmonary fibrosis. In addition, the levels of tumour necrosis factor-α (TNF-α) and transforming growth factor β1
(TGF-β1) were reduced by endostatin treatment. Furthermore, endostatin decreased alveolar type II cell apoptosis
and had an epithelium-protective effect. These might be the mechanism underlying the preventive effect of
endostatin on pulmonary fibrosis.
Conclusions: Our findings suggest that endostatin treatment inhibits the increased MVD, inflammation and alveolar
epithelial cell apoptosis, consequently ameliorating BLM-induced pulmonary fibrosis in rats.
Keywords: Endostatin, Bleomycin, Pulmonary fibrosis, Angiogenesis, Vascular endothelial growth factor, Extracellular
signal-regulated protein kinase 1/2, Inflammation, Epithelial cell apoptosisBackground
Idiopathic pulmonary fibrosis (IPF) is a chronic and dis-
abling lung disease with a high mortality rate due to ul-
timate respiratory failure [1]. The mean survival time
varies from 3.2 to 5 years after diagnosis [2,3]. The
therapeutic options are limited and often disappointing
[4-6]. Although the aetiology remains unknown, aber-
rant angiogenesis plays an important role in the devel-
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reproduction in any medium, provided the ordemonstrated that the inhibition of vascular remodelling
attenuates pulmonary fibrosis in animal models [7-13].
Among the numerous cytokines related to angiogen-
esis, vascular endothelial growth factor (VEGF) has been
recognised as an important regulator of angiogenesis
and a major enhancer of vascular permeability in several
types of inflammatory lesions [10,14]. It is essential for
endothelial cell survival, proliferation and tube forma-
tion. The biological functions of VEGF polypeptides re-
sult from binding to two cellular receptors, VEGFR1
(Flt-1) and VEGFR2/KDR (Flk-1), on endothelial cells.
Signalling through Flk-1 is responsible for the vascular
homeostasis and survival functions of VEGF [14]. Fur-
thermore, VEGF has been reported to recruit leukocytesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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injury by stimulating the expression of MCP-1 [15].
VEGF regulates endothelial cell morphology and acti-
vates multiple signal transduction pathways, including
extracellular signal–regulated kinase (ERK1/2) [16],
which is involved in regulating the angiogenesis and
inflammation response in the lung. A previous study
[17] confirmed that VEGF exacerbates pulmonary fi-
brosis, suggesting that VEGF facilitates the fibrogenic
process. VEGF inhibition is being tested as a strategy
for the prevention of angiogenesis and vascular leakage
in pulmonary fibrosis.
Endostatin, a 20 kDa carboxyl-terminal proteolytic
fragment of collagen XVIII, has been thoroughly studied
as a potent inhibitor of angiogenesis since its discovery
by O’Reilly et al. in 1997 [18]. Endostatin inhibits endo-
thelial cell proliferation, migration/invasion, and tube
formation [19] and induces endothelial cell apoptosis
[20]. Endostatin has been shown to inhibit new blood
vessel formation under different pathological conditions
characterised by increased angiogenesis, such as tu-
mours [18], endometriosis [21], arthritis [22], ulcerative
colitis [23] and other diseases in many experimental
models.
Endostatin interferes with VEGF/VEGFR signalling
[24,25]. Endostatin has been reported to ameliorate peri-
toneal sclerosis by reducing expression of transforming
growth factor β1 (TGF-β1) [26], which is the most im-
portant profibrotic growth factor.
In addition, endostatin suppresses the produc-
tion of the proinflammatory cytokine tumour necrosis
factor-α (TNF-α) [22]. VEGF, TGF-β1 and TNF-α are
overexpressed in the early stages of pulmonary fibrosis.
Isobe [27] found that endostatin neutralisation treat-
ment in a rat myocardial infarction (MI) model
resulted in increased angiogenesis, exaggerated tissue
remodelling and interstitial fibrosis in post-MI hearts.
On the basis of these reports, we hypothesise that
endostatin may have protective effects, particularly by
inhibiting angiogenesis, in the pathogenesis of pul-
monary fibrosis. To test this hypothesis, the in vivo effect
of endostatin on BLM-induced lung injury and fibrosis in
rats was investigated. We assessed the antiangiogenic effi-
cacy of endostatin treatment and also investigated its effect
on VEGF signal transduction. We show that endostatin
prevents BLM-induced pulmonary fibrosis in rats through
the reduction of aberrant angiogenesis, proinflammatory
cytokine production and alveolar epithelial cell apoptosis.
Methods
Animals and drugs
One hundred pathogen-free 8-week-old Sprague–Dawley
(SD) male rats weighing 200–250 g were purchased from
the Laboratory Animal Center, Shandong University oftraditional Chinese medicine. This study was approved
by the Shandong Animal Care and Use Committee and
followed the national and institutional rules concerning
animal experiments. Rats were housed at 23 ± 2°C and
55 ± 5% humidity, with a 12 h light–dark cycle. Rodent
food and water were provided ad libitum. The rats were
maintained for 1 week before the start of experiments to
adapt to the environment. Experimental animals were
treated in accordance with the criteria outlined in the
Guide for the Care and Use of Laboratory Animals.
Bleomycin hydrochloride, purchased from Tianjin
Taihe Pharmaceutical Co. (Tianjin, China), was dissolved
in sterile 0.9% saline on the day of intratracheal instilla-
tion at a dose of 5 mg/kg per rat. Recombinant human
endostatin was provided by Jiangsu Simcere Medgenn
Bio-Pharmaceutical Co. Ltd. (Nanjing, China), and
injected at a dose of 2 mg/kg body weight per rat.
Animal model of BLM-induced pulmonary fibrosis
The rats were randomly divided into five groups: (A)
saline only (control group, SA group); (B) BLM only
(BLM group); (C) BLM plus early endostatin treatment (E-
ES group); (D) BLM plus late endostatin treatment (L-ES
group); and (F) BLM plus whole-course endostatin treat-
ment (W-ES group).
Animals were anaesthetised with an intraperitoneal in-
jection of sodium pentobarbital (20 mg/kg) and then
given an intratracheal instillation of 5 mg/kg BLM. The
rats were rotated immediately after BLM instillation to
ensure thorough drug distribution in the lungs. Control
animals received an equal volume of sterilised saline
using the same procedure. After recovery from the an-
aesthesia, the rats were returned to their cages and
allowed food and water as normal.
To clarify the effect of endostatin on different stages
of BLM-induced pulmonary fibrosis development,
endostatin was administered daily through subcutaneous
injection (2 mg/kg body weight) at the early phase (from
days 1–14), the late phase (from days 15–28) or during
the entire course (from days 1–28) after BLM infusion.
Rats from each group were divided into four subgroups,
which were sacrificed on days 3, 7, 14 and 28. Blood was
collected from the abdominal aorta and centrifuged at
2500 rpm for 10 min. The serum was stored at −80°C.
Histological examination
After sacrifice, the left lungs were fixed in 4% parafor-
maldehyde, dehydrated, and embedded in paraffin. The
tissues were then sectioned at 5 μm and stained with
haematoxylin & eosin (H&E) and Masson's trichrome to
examine the degree of fibrosis. Ten fields in each section
were analysed. The severity of fibrotic changes in each
histological section of the lung was assessed as the mean
score of severity from the observed microscopic fields
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Ashcroft and co-workers [28].
Hydroxyproline assay of lung tissues
Hydroxyproline was measured using the hydroxyproline
test kit from the Nanjing Jiancheng Bioengineering Insti-
tute according to the manufacturer’s instructions. In
brief, 30–100 mg of lung tissue was hydrolysed in 1 ml
lysis buffer solution (pH 7.4, 10 mM Tris–HCl, 0.1 mM
EDTA–2Na, 10 mM saccharose, and 0.8% sodium chlor-
ide solution) at 100°C for 20 min, and the hydroxypro-
line concentration was determined according to Otsuka’s
previously published method [29]. Data were expressed
as micrograms of hydroxyproline per gram of wet lung
weight.
Immunohistochemical analysis
After deparaffinisation in xylene and hydration with
graded alcohol, the sections were incubated in citrate
buffer (pH 6.0) at 96°C for 20 min to retrieve the
antigen. After cooling at room temperature, the sections
were placed in 3% hydrogen peroxide (H2O2) for 15 min
at room temperature to inactivate endogenous peroxi-
dases. After washing with PBS three times, the sections
were blocked with rabbit serum for 30 min, followed
by incubation with primary antibodies against the
CD31 antigen (1:200, Santa Cruz Biotechnology,
California, USA) and Flk-1 (1:200, Beijing Biosynthesis
Biotechnology Co., Ltd., China) at 4°C overnight. After
washing with PBS, the sections were incubated in
biotinylated rabbit anti-goat antibody for 30 min at
37°C. Then, the sections were washed in PBS, and
the ABC reagent was applied (Wuhan Boster Bio-
logical Technology Ltd, China). Antibody binding was
detected with a diaminobenzidine kit, and the sections
were counterstained with haematoxylin.
Microvessel density (MVD) was assessed by two inde-
pendent observers as reported by Weidner [30]. Briefly,
MVD was recorded as the number of CD31-positive
endothelial cells or endothelial cell clusters per high-
power field (× 200) from the five areas of highest vas-
cularisation. Vessels with thick muscular walls were
excluded. Flk-1 was evaluated using immunostaining
scores (range 0–5), which were calculated by adding
the distribution (none = 0, focal = 1, multifocal = 2, and
diffuse = 3) to the intensity of the staining (none = 0,
mild = 1, and strong = 2) [31].
Bronchoalveolar lavage
After the rats were sacrificed by arterial exsanguination,
the chest cavity was opened with a midline incision. The
right main bronchus was ligated. Bronchoalveolar lavage
was performed only from the left lung through a tra-
cheal cannula with 3 ml cold PBS (pH 7.4). Thisprocedure was repeated five times. Fluid recovery was
consistently above 85%. Total cell counts were obtained
in bronchoalveolar lavage fluid (BALF) using a haemo-
cytometer. After centrifugation at 4°C and 1000 × g for
10 min, the cell-free supernatant was collected and
stored at −80°C for biochemical measurements. The cell
pellet was resuspended in cold PBS, smeared on a glass
slide, air dried, and stained with Wright-Giemsa to iden-
tify different cell types. Two hundred cells from each
animal were counted and expressed as a percentage of
total cells. The protein permeability index (PPI) was cal-
culated as BALF total protein/plasma total protein × 100,
as described previously [32].
Real-time PCR
Total RNA was extracted from frozen lung tissues
using Trizol (Takara Bio Inc. Japan) according to
the manufacturer's instructions. Real-time PCR was
performed with a Lightcycler480 (Roche) using the
SYBR Green assay after reverse transcribing 1 μg of
RNA with reverse transcriptase. All the results were
normalised to the levels of β-actin mRNA. The primer
pairs and expected lengths (in bp) were as follows
(5' to 3'): VEGFA (GenBank: NM_001110333.1, for-
ward: GTCCTCACTTGGATCCCGACA, reverse: CCT
GGCAGGCAAACAGACTTC; 99 bp), Flk-1 (GenBank:
NM_013062.1, forward: AATGCCCATGACCAAGAATG
TG, reverse: GGATAGAGCCGCGTGTCTGAA; 129 bp),
and β-actin (GenBank: NM_031144.3, forward: CTAAGGC
CAACCGTGAAAAGA, reverse: CCAGAGGCATACAGG
GACAAC; 103 bp). The cycling conditions were as follows:
95°C for 30 s, followed by 40 cycles of 95°C for 5 s, 65°C
for 30 s, and 65°C for 15 s. Relative gene expression was
calculated as 2−ΔΔCT[33].
Enzyme-linked immunosorbent assay analysis
The concentrations TGF-β1 (active form) and VEGF in
lung tissue lysates and TNF-α in BALF were measured.
Briefly, 100 mg of lung tissue from both control and
treated animals was homogenised in 1 ml 50 mM Tris–
HCl (pH 7.4) containing 1% NP-40, 50 mM NaCl, 0.5
mM ethylene diamine tetraacetic acid (EDTA), and 100
mM phenylmethylsulfonyl fluoride (PMSF) [34]. The
protein concentration in each sample was determined
using the bicinchoninic acid (BCA) method according to
the manufacturer’s instructions. Levels of TGF-β1, VEGF
and TNF-α were measured using quantitative ELISA kits
according to the manufacturer’s protocols (R&D Sys-
tems, Minneapolis, MN).
Western blot
Protein samples (40 μg) were separated on precast 10%
SDS polyacrylamide gels (SDS-PAGE). After electro-
phoresis, the proteins were transferred to PVDF
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The membranes were incubated overnight at 4°C with
primary rabbit polyclonal phosphorylated ERK1/2
(pERK1/2) and ERK (1:2000 dilutions in 5% BSA in
TBS-T; Cell Signaling, Beverly, MA). After washing
three times in TBS-T, horseradish peroxidase (HRP)-
conjugated secondary antibodies were used at a dilution
of 1:5000 in TBS-T for 1 h at room temperature. After
three additional washes with TBS-T, the immunoreactive
bands were visualised with a chemiluminescence reagent
(ECL, Millipore Biotechnology Inc., USA) and quantified
using Multi Gauge V3.2 (Fuji Film, Japan) Analysis
Software.
Quantitation of alveolar epithelial cell apoptosis
To evaluate the apoptosis of alveolar epithelial cells, ter-
minal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) and immunofluorescent double-
staining of surfactant protein C (SP-C) were performed
on lung sections on days 7 and 28. TUNEL assay was
conducted by using the In Situ Cell Death detection kit
(TMR red, Roche, Mannheim, Germany) according to
the manufacturer’s instructions. Briefly, deparaffinized
sections were permeablized with proteinase K (20 μg/ml
in PBS) for 15 min at 37°C. After washing with PBS, the
sections were then treated with TUNEL reaction mixture
containing TdT and fluorescein isothiocyanate-labelled
dUTP for 60 min at 37°C. SP-C (Wuhan Boster Bio-
logical Technology Ltd, China) was used to identify al-
veolar epithelial cells. Goat anti-rabbit IgG-FITC was
used as the secondary antibody. The nuclei were stained
with 4', 6'-diamidino-2-phenylindole (DAPI). Ten high-
power fields of each section were randomly selected
under a fluorescence microscope, and the numbers of
TUNEL-positive cells and SP-C-positive cells were
recorded [35].
Statistical analysis
All results were expressed as the mean ± SD. A two-way
ANOVA with multiple comparison tests to assess differ-
ences between groups was performed. All data analysis
was performed using SPSS 18.0 software. Statistical
graphs were generated with GraphPad Prism 5 software.
P values less than 0.05 were considered statistically
significant.
Results
Effect of endostatin on BLM-induced pulmonary fibrosis
We evaluated the effect of endostatin treatment in the
BLM-induced lung fibrosis model. Lung fibrosis was
assessed by morphometry of Masson's trichrome-stained
lung sections and hydroxyproline deposition in lung tis-
sue. Masson and H&E staining demonstrated that BLM
treatment significantly induced distortion of the lungstructure and collagen deposition in the lungs, whereas
well-alveolised normal histology was observed in the sa-
line control group (Figure 1A,B). The administration of
endostatin for the first 14 days or throughout the course
of the experiment effectively ameliorated BLM-induced
pulmonary fibrosis compared to the control, whereas the
histopathological characteristics of the L-ES group were
not significantly different from the BLM group. To grade
the extent of lung fibrosis, the fibrotic changes in the
lung were assessed using the Ashcroft score. The scores
of the E-ES and W-ES groups were significantly lower
than the BLM group on days 7, 14 and 28 after BLM ad-
ministration (Figure 1C).
The collagen content of rat lungs was assessed using
the hydroxyproline assay. The concentration of hydroxy-
proline in the lung tissue at 28 days after BLM injection
was significantly increased in the BLM group compared
with the saline control group (Figure 1D). In the E-ES
and W-ES groups, the hydroxyproline content was sig-
nificantly decreased compared with the BLM group on
days 7, 14 and 28. No significant difference in Ashcroft
score or hydroxyproline content was observed in the L-
ES group compared to the BLM group. The hydroxypro-
line content was lower in the L-ES group than in the
BLM group, although this difference was not statistically
significant (P = 0.09 on day 28).Effect of endostatin on the inflammation response in
BLM-induced pulmonary fibrosis
The early response to BLM challenge is characterised by
a dramatic increase in inflammatory cell recruitment. To
investigate the effect of endostatin on the inflammation
response induced by BLM infusion in rats, we assessed
the inflammatory cell count and the concentration of
the pro-inflammatory cytokine TNF-α in BALF.
The total and differential cell counts in BALF for each
day were presented in Figure 2. The total number of
cells was significantly increased at all time points in the
BLM-treated rats. The number of neutrophils in the
BALF after BLM infusion peaked on day 7 and de-
creased from day 14 to day 28 but was still elevated
compared to the saline control group. Treatment with
endostatin significantly inhibited the accumulation of
total leukocytes in BALF on days 3, 7 and 14 after BLM
challenge (Figure 2A), which appeared to be caused by a
significant decrease in neutrophil recruitment on days 3,
7 and 14 (Figure 2B). There was no change in lympho-
cyte number between BLM groups and the groups ad-
ministered endostatin (Figure 2C). The number of
macrophages was significantly decreased by endostatin
treatment on days 7 and 14 (Figure 2D). No differences
in total or differential cell count were observed between
the L-ES and BLM groups.
Figure 1 Effect of endostatin on BLM-induced pulmonary fibrosis. (A) Representative images of hematoxylin and eosin (H&E) and (B)
Masson trichrome –stained sections of rats in each experimental group on day 28 (×200). (C) Comparison of the Ashcroft score among the
experimental groups. (D) Collagen deposition was assessed by measuring the hydroxyproline content. Bar = 100μm. Results are expressed as
mean ± SD, n = 5 in each group, *P < 0.001 vs SA group; #P < 0.05 vs BLM group; △P < 0.01 vs BLM group; +P < 0.001 vs BLM group.
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BLM group was observed on day 3, and the concentra-
tion gradually declined on days 7, 14 and 28, although
levels remained significantly higher than in the saline
group at each timepoint studied. Compared with the
BLM group, the concentrations of TNF-α in the E-ES and
W-ES groups were significantly decreased (Figure 2E), and
late endostatin administration produced a similar effect
(P < 0.05 on day 28).
Vascular permeability plays a key role in leukocyte and
protein leakage. In our study, we assessed the PPI as the
ratio of BALF to plasma protein, which was alsosuppressed by endostatin administration at early stages
in the E-ES and W-ES groups, as depicted in Figure 2F.
Effect of endostatin on MVD in BLM-treated rat lung
tissues
Endostatin possesses antiangiogenic activities. To ex-
plore the effect of endostatin on angiogenesis in BLM-
induced pulmonary fibrosis, we quantified MVD in the
lung by immunostaining for the endothelial marker
CD31. The number of CD31-positive vessels was in-
creased in BLM-treated lungs on day 3 and peaked at
day 7, gradually declining with the aggravation of lung
Figure 2 Effect of endostatin on the inflammatory response in BLM-induced pulmonary fibrosis. Changes in (A) total cell count, (B)
neutrophils, (C) lymphocytes, (D) macrophages and (E) TNF-α expression in BALF of rats at each stage were presented. (F) Representative PPI
change, calculated as BALF total protein/plasma total protein × 100. Results are expressed as mean ± SD, n = 4 or 5 in each group, *P < 0.001 vs
SA group; $P < 0.05 vs SA group; #P < 0.05 vs BLM group; +P < 0.001 vs BLM group.
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creased the number of CD31-positive cells at each stage
compared to the BLM-only group levels (Figure 3). The
antiangiogenic effect was particularly striking on day 7.
Effect of endostatin on VEGF/Flk-1 expression in BLM-
induced pulmonary fibrosis
VEGF mRNA expression in lung tissue, measured using
real-time PCR, increased markedly 3–7 days after BLM
instillation. It decreased slightly on day 14 and stronglydecreased by day 28 (Figure 4A). The VEGF level in the
E-ES and W-ES groups was lower than the BLM group
at each stage, as depicted in Figure 4A. The expression
of Flk-1 mRNA in rats from the BLM group was higher
than in the saline group at each time point after BLM
infusion (Figure 4B). Early endostatin administration ef-
ficiently inhibited Flk-1 mRNA expression at each
timepoint studied compared to the BLM group. How-
ever, no differences in the mRNA expression of VEGF or
Flk-1 were detected between the L-ES and BLM groups.
Figure 3 Effect of endostatin on MVD in BLM-induced pulmonary fibrosis. Immunohistochemical staining of CD31 in lung sections in SA
(A), BLM (B) and E-ES (C) groups on day 7 (×200). (D) MVD was assayed by counting the number of the microvessels per high power field in lung
sections stained with antibody CD31. Bar = 100μm. *P < 0.001 vs SA group; #P < 0.01 vs BLM group; +P < 0.001 vs BLM group.
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similar to the mRNA changes, as assessed by the VEGF
concentration in lung tissue lysates (Figure 5A) and Flk-
1 immunostaining scores (Figure 5B), which were also
reduced in BLM-treated rats by early endostatin treat-
ment at each stage studied.
Effect of endostatin on TGF-β1 expression in lung tissue
lysates
TGF-β1 is considered one of the most important fibro-
blast stimulators leading to pulmonary fibrosis. We mea-
sured the TGF-β1 concentration in lung tissue lysates by
ELISA. The TGF-β1 concentration increased at all time
points examined after BLM challenge. Early endostatin
administration reduced BLM-induced TGF-β1 expres-
sion on days 3, 7, 14 and 28 after BLM infusion
(Figure 6). TGF-β1 Level was lower in the L-ES group
than in the BLM group on day 28, although late
endostatin treatment did not produce a statistically sig-
nificant effect (P = 0.142 on day 28).
Effect of endostatin on ERK1/2 phosphorylation in BLM-
induced pulmonary fibrosis
ERK activation plays an important role in angiogenesis
and inflammation during pulmonary fibrosis. We evalu-
ated whether ERK1/2 phosphorylation levels in rat lungs
after BLM challenge were altered by endostatin adminis-
tration. Western blot analysis showed that BLMchallenge caused a significant increase in pERK1/2 com-
pared to saline infusion, whereas endostatin treatment
resulted in a significant decrease in pERK1/2 expression
(Figure 7). No significant differences were observed in
the pERK1/2 expression levels between the L-ES and
BLM groups. The total steady-state protein levels
remained unchanged.
Effect of endostatin on alveolar epithelial cell apoptosis
We counted the numbers of SP-C, a marker of alveolar
type II cells, and TUNEL double-positive cells in the
lung sections to detect apoptosis of alveolar epithelial
cells. As shown in Figure 8, BLM induced maximum al-
veolar type II cell apoptosis on day 7, and the apoptosis
decreased on day 28. Early endostatin administration de-
creased the numbers of apoptotic type II cells on day 7.
The whole-course endostatin treatment also produced a
similar effect (P = 0.03 on day 28), but there were no sig-
nificant differences in epithelial cell apoptosis among
BLM, E-ES and L-ES groups on day 28.
Discussion
IPF is an important health problem in humans, and the
precise pathogenic mechanisms remain unknown. BLM
can cause toxicity by generating an acute inflammatory
response and fibrosis in a short period, whereas IPF has
a slow and irreversible progression in patients. Histo-
logical hallmarks present in BLM-treated rats, such as
Figure 4 Effect of endostatin on VEGF/Flk-1 mRNA expression
in BLM-induced pulmonary fibrosis. (A) VEGF mRNA and (B) Flk-1
mRNA expression were measured by real-time PCR. Results are
expressed as mean ± SD, n = 5 in each group, *P < 0.001 vs SA
group; $P < 0.05 vs SA group; #P < 0.05 vs BLM group; +P < 0.001 vs
BLM group.
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obliteration of the alveolar space, are similar to IPF pa-
tients [36]. The intratracheal instillation of BLM into ro-
dents is widely used as an in vivo experimental model
for the study of human pulmonary fibrosis. Emerging
evidence has demonstrated that angiogenesis is import-
ant in the development and progression of pulmonary fi-
brosis [8,9,11,13]. In the present study, endostatin was
administered at different phases of BLM-induced lung
injury and fibrosis in rats. We demonstrated that
endostatin treatment had the following effects: (1) de-
creasing collagen deposition and hydroxyproline con-
tent; (2) reducing MVD and VEGF/VEGFR-2 (Flk-1)
expression; (3) inhibiting ERK1/2 activation; and (4) re-
ducing the increased number of inflammatory cells
present in BALF and decreasing the production of theproinflammatory and fibrotic cytokines TNF-α and
TGF-β1; (5) inhibiting the alveolar epithelial cell apop-
tosis. From these findings, we conclude that endostatin
may play an important role in the course of pulmonary
fibrosis induced by BLM, which may be mediated
through its potentially regulatory effects on inhibiting
VEGF receptor and ERK1/2 activation.
Endostatin has potent antiangiogenic and antitumour
activity through inhibiting the proliferation and migra-
tion of endothelial cells [18]. Endostar, a novel modified
human recombinant endostatin with an additional nine
amino acids purified from Escherichia coli, was approved
for the treatment of non–small cell lung cancer in com-
bination with other chemotherapy drugs in China in
2005 [37]. Elevated levels of endostatin are observed in
the BALF and serum of IPF patients, especially those
with severe respiratory dysfunction, compared to pa-
tients without these clinical manifestations [38,39]. A
previous study [40] showed that recombinant endostatin
inhibited dermal fibrosis in an ex vivo human skin
model, and a peptide derived from endostatin prevented
dermal and lung fibrosis induced by BLM in a mouse
model. The endostatin peptide has also been found
to prevent the progression of peritoneal sclerosis,
characterised by progressive fibrosis in the peritoneum,
in a mouse experimental model [26]. These studies
suggest that endostatin has an anti-fibrotic effect and
may have therapeutic potential for preventing or revers-
ing organ fibrosis. Similarly, in a study performed
by Isobe et al. [27], endostatin expression levels in
cardiomyocytes and endostatin serum levels were signifi-
cantly elevated, and neutralisation of endostatin exacer-
bated the tissue remodelling and interstitial fibrosis in a
rat myocardial infarction model and caused increased
tissue collagen and MMP-2/9 activity. Our study found
that exogenous endostatin could reduce MVD and colla-
gen deposition in BLM-induced pulmonary fibrosis in
rats. On the basis of these reports and our research, we
propose that increased endostatin levels in fibrotic lung
tissues might establish a negative feedback regulatory
loop, which decreases collagen XVIII and MMP-2/9
levels and has a protective effect on the progression of
fibrosis. When fibrotic lung tissues are treated with ex-
ogenous endostatin, significant positive effects on dis-
ease progression should be observed.
Aberrant angiogenesis has been implicated in the de-
velopment and progression of pulmonary fibrosis.
Turner-Warwick [41] originally demonstrated the exist-
ence of morphologic neovascularisation in the lungs of
IPF patients. Further evidence also strongly suggests a
role for angiogenic vascular remodelling in pulmonary
fibrosis, and emerging studies indicate that angiogenesis
is a central hallmark for the progression of IPF [13,42].
Angiogenesis is regulated by a balance between the
Figure 5 Effect of endostatin on VEGF/Flk-1 protein expression in BLM-induced pulmonary fibrosis. (A) VEGF concentration in lung tissue
lysates and Flk-1 immunostaining scores (B) among different experimental groups were presented. Immunohistochemical staining of Flk-1 in lung
sections in BLM (C) and E-ES (D) groups on day 7 (×200) were presented. Results are expressed as mean ± SD, n = 5 in each group, *P < 0.001 vs
SA group; $P < 0.05 vs SA group; △P < 0.01 vs BLM group; #P < 0.05 vs BLM group; +P < 0.001 vs BLM group.
Figure 6 Effect of endostatin on expresion of TGF-β1 in lung
tissue lysates. TGF-β1 concentrations in lung tissue lysates among
different experimental groups were presented. Results are expressed
as mean ± SD, n = 5 in each group, *P < 0.001 vs SA group; #P < 0.05
vs BLM group; +P < 0.001 vs BLM group.
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growth. VEGF is the principal angiogenic factor and is
proven to be a proinflammatory and permeability-
inducing factor in BLM-induced pulmonary fibrosis [12].
Based on this information, inhibition of the VEGF/
VEGFR pathway in PF may have protective effects
against angiogenesis and fibrogenesis. Indeed, in an on-
going clinical trial, VEGF is the major target for IPF
treatment using a tyrosine kinase inhibitor, which is cur-
rently in phase 3 (NCT01335464) [43]. Endostatin in-
hibits VEGF-mediated signalling through a direct
interaction with Flk-1 [25,37]. In our study, we used
endostatin in the BLM-induced lung fibrosis model. We
noted a pronounced decrease in VEGF and Flk-1 expres-
sion after endostatin administration, particularly when
administered at early stages of disease progression.
Meanwhile, the exacerbated MVD was reduced signifi-
cantly. This finding supports a contribution of VEGF to
the fibrotic process via angiogenesis induction [17]. Fur-
thermore, transient protein leakage following BLM can
aggravate the initial injury and thereby promote
fibrogenesis. VEGF is a major enhancer of vascular
permeability [14]. Our study showed that endostatin
down-regulated the VEGF-related protein permeability
index. In this experiment, we assessed the antiangiogenic
Figure 7 Endostatin suppressed the ERK1/2 phosphorylation. (A) Western blot showed pERK1/2 protein expression among different
experimental groups on days 3, 7, 14 and 28. (B) Quantitative densitometry analysis of western blot analysis for pERK1/2. Data are presented as
the ratio pERK1/2 and ERK. Results are expressed as mean ± SD, n = 3 in each group, *P < 0.01 vs SA group; $P < 0.05 vs SA group; #P < 0.05 vs
BLM group; +P < 0.001 vs BLM group.
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http://respiratory-research.com/content/14/1/56efficiency of endostatin and the downregulation of
VEGF production in inhibiting BLM-induced pulmonary
fibrosis.
ERK is involved in the regulation of lung angiogen-
esis and inflammation. Recent reports have shown that
ERK1/2 activation is increased in an animal model of
pulmonary fibrosis, and inhibiting ERK1/2 activation
suppresses lung collagen deposition and inflammation
and consequently ameliorates pulmonary fibrosis
[44,45]. Western blots of human lung biopsy samples
also demonstrate significantly increased ERK1/2 sig-
nalling in IPF samples compared with normal controls
[46]. These findings support ERK1/2 activation playing
an important role in pulmonary fibrosis. In our study,
we demonstrated that endostatin treatment reducedFigure 8 Effect of endostatin on alveolar epithelial cell apoptosis. (A-
DAPI (C) identifies apoptotic alveolar type II cells (D, merge) from a lung s
(F) and E-ES (G) groups on day 7 (×400) are shown. (F) Quantitative assessm
groups on days 7 and 28 were presented. Bar = 100μm. Results are express
#P < 0.05 vs BLM group; +P < 0.001 vs BLM group.phosphorylated ERK1/2 overexpression and MVD in
the lungs of BLM-treated rats. VEGF overexpression
strongly activates ERK1/2, resulting in vascular mor-
phological changes [16]. Endostatin treatment decreases
VEGF expression and induces ERK1/2 dephosphoryla-
tion, resulting in the retraction of newly formed vessels
[47]. Furthermore, TGF-β1 plays a critical role in stimu-
lating myofibroblast differentiation, proliferation and
extracellular matrix (ECM) production in pulmonary
fibrosis. Our results showed that endostatin reduced
TGF-β1 expression in rat lungs after BLM challenge,
similar to the results of Sullivan and colleagues, which
showed that inhibition of the ERK pathway markedly re-
duced TGF-β1 expression induced by TNF-α in lung
fibroblasts [48].D) Representative co-immunofluorescence for TUNEL (A), SP-C (B) and
ection. (E-G) Representative fluorescent micrographs for in SA (E), BLM
ent of alveolar type II cell apoptosis among different experimental
ed as mean ± SD, n = 5 in each group, *P < 0.001 vs SA group;
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http://respiratory-research.com/content/14/1/56The inflammatory response was the initial response
following BLM administration in our animal model.
Angiogenesis is proinflammatory due to enhanced adhe-
sion and permeability in inflammatory lesions [49]. Peri-
vascular inflammatory cell infiltrates are found in the
lungs of pulmonary fibrosis patients. Increasing evidence
suggests an important role for endostatin in inflamma-
tory reactions. Yin and colleagues [50] found that
endostatin gene expression inhibited the development of
arthritis, an inflammatory angiogenic disease, in TNF-
transgenic mice. Yue L et al. [22] showed that recombin-
ant human endostatin decreased IL-1β and TNF-α levels
produced by synoviocytes derived from adjuvant arthritis
rats. Consequently, endostatin contributes to the regres-
sion of rat adjuvant arthritis, which is related to its anti-
angiogenic properties and inhibition of proinflammatory
cytokines. Abdollahi and colleagues [51] demonstrated
that endostatin inhibits TNF-α-induced angiogenic sig-
nalling by downregulating TNFR1 expression. In the
present study, endostatin administration not only
inhibited aberrant angiogenesis in the lung but also de-
creased inflammatory cell numbers in the BALF of the
BLM model. The anti-inflammatory effect of endostatin
may be partly due to the following mechanisms: (1) in-
hibition of inflammatory cell migration and vascular
leakage related to VEGF; (2) attenuation of TNF-α ex-
pression, an angiogenic cytokine and one of the most
potent proinflammatory cytokines promoting inflamma-
tory cell infiltration in the rat lung; and (3) decreased
TGF-β1 levels and inhibition of inflammatory cell
chemotaxis in the lung. These results suggest that
endostatin treatment may alter the course of the inflam-
matory process associated with pulmonary fibrosis.
Given the important role of epithelial cell apoptosis in
human IPF [52], alveolar type II cells apoptosis was
detected in our study. Richter et al. [39] indicated that
endostatin reduces epithelial proliferation and wound re-
pair in a FasL and caspase dependent manner in vitro.
However, we here showed that BLM-induced pulmonary
injury and alveolar type II apoptosis were suppressed in
endostatin treated rats in the early stage. Inflammation
can lead to increased alveolar epithelial cell apoptosis
[53]. The epithelium-protective effect of endostatin in
the early stage may be secondary to the reduced vascular
permeability and decreased inflammation in vivo experi-
ments. Furthermore, maybe it related to the reduced
level of TGF-β1, which is an enhancer of Fas-mediated
apoptosis of lung epithelial cells [54]. Additionally, al-
though it was reported that physiological doses of
endostatin reduced epithelial cell wound repair in vitro
[39], in our in vivo experiment, exogenous endostatin
used in microgram amounts, a supraphysiological doses,
produced a protective effect on epithelial cell apoptosis
in rat model of pulmonary fibrosis. The effects ofendostatin on these mechanisms warrant further
investigation.
Conclusion
Taken together, endostatin plays a complex role in BLM-
induced pulmonary fibrosis. Our findings demonstrated
that endostatin blocked VEGF/Flk-1 signalling and di-
minished ERK1/2 phosphorylation, inhibiting the in-
creased MVD. Meanwhile, endostatin decreased TNF-α
and TGF-β1 production, leukocyte trafficking and pro-
tein leakage. Furthermore, endostatin decreased alveolar
epithelial cell apoptosis. Our results support the hypoth-
esis that early endostatin administration attenuates the
progression of pulmonary fibrosis by inhibiting angio-
genesis, inflammation and epithelial cell apoptosis. The
pathogenesis of pulmonary fibrosis is likely complex, in-
volving multiple pathways. Endostatin treatment amelio-
rated BLM-induced pulmonary fibrosis but was not able
to completely prevent or reverse the fibrotic process.
Further studies in existing fibrosis models are necessary.
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